Boston Trust Walden Corp Has $52.56 Million Holdings in Oracle ...
📉 Boston Trust Walden Corp decreased its Oracle holdings by 10.1% in Q1, selling 40,131 shares and retaining a $52.56 million position.
📈 Several smaller institutional investors increased stakes, with HFM Investment Advisors raising their position by 290.9% to own 129 shares.
💰 Oracle reported Q1 revenue of $19.18 billion, surpassing analyst estimates of $19.10 billion by $80 million.
📊 The company achieved earnings per share of $2.11, beating the consensus estimate of $1.96 by $0.15.
🚀 Revenue grew 20.6% year-over-year, driven by expansion in cloud infrastructure and enterprise software applications.
🎯 Analysts maintain a 'Moderate Buy' consensus with an average price target of $268.27, well above current trading levels.
🏦 Bank of America upgraded its price objective to $240 and reaffirmed a 'Buy' rating on the stock.
💵 Oracle declared a quarterly dividend of $0.50 per share with an ex-dividend date of July 10th.
📉 The stock trades at a PE ratio of 24.06 with a market capitalization of $404.04 billion.
🔮 Management provided Q1 2027 EPS guidance ranging from $1.72 to $1.76 per share.
- Oracle reported revenue of $19.18 billion, exceeding analyst estimates of $19.10 billion and demonstrating strong top-line growth.
- The company posted earnings per share of $2.11, beating the consensus estimate of $1.96 by a significant margin of $0.15.
- Revenue increased 20.6% compared to the same quarter last year, indicating robust demand for cloud and enterprise solutions.
- Net margin reached 25.37% with a return on equity of 58.62%, highlighting efficient operations and strong profitability.
- Bank of America raised its price objective to $240 and issued a 'Buy' rating, signaling confidence in future upside.
- The stock trades at a PEG ratio of 0.89, suggesting the current valuation may be reasonable relative to growth prospects.
- Management provided forward guidance for Q1 2027 EPS between $1.72 and $1.76, indicating sustained earnings visibility.
- Boston Trust Walden Corp reduced its position by 10.1% in the first quarter, signaling a decrease in confidence from a major institutional holder.
- The stock price has fallen significantly from a 52-week high of $345.72 to recent levels around $140, reflecting substantial market correction.
- Stephens reissued an 'Equal Weight' rating with a lower price target of $164, indicating some analysts see limited near-term upside.